Novartis (NVS) said Monday that its radioligand therapy, Pluvicto, combined with standard care, significantly improved radiographic progression-free survival in a pre-specified interim analysis of a phase 3 trial for patients with a certain type of prostate cancer.
The drugmaker said a positive trend in overall survival was also observed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.